MetroNIDAZOLE

C. diff Risk

Low

Oral Bioavailability

NA

Approximate Cost

<$1/day (Oral)

Spectrum Of Activity

General Information

Drug Monitoring

Neurologic side effects including peripheral, optic neuropathy, aseptic meningitis, encephalopathy, reversible cerebellar lesions

First Line Indications

  • Treatment of C. difficile colitis

  • Treatment of infections or abscesses where anaerobes are major pathogens in combination with another agent for aerobic bacteria

Oral Liquids

Concentration: 50 mg/mL

Taste: Unpleasant taste

Not all strengths of oral liquids are listed nor be available on the CHEO Formulary

Tablet/Capsule Strengths

  • 250 mg

Tablets or capsules are preferred especially over an unpleasant tasting oral liquid.

Not all strengths of oral tablets/capsules are listed and they are not all available on the CHEO Formulary.